Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?

2008 ◽  
Vol 39 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Peter Hellstern
1985 ◽  
Vol 40 (4) ◽  
pp. 385-387 ◽  
Author(s):  
Arthur Dresdale ◽  
Frederick O. Bowman ◽  
James R. Malm ◽  
Keith Reemtsma ◽  
Craig R. Smith ◽  
...  

Author(s):  
Emma D Bainbridge ◽  
Priscilla Y Hsue ◽  
Jonathan H Esensten ◽  
Kara L Lynch ◽  
Carolyn M Hendrickson ◽  
...  

Abstract We characterized the antibody composition of COVID-19 convalescent plasma (CCP) and the immunologic responses of hospitalized COVID-19 patients after receiving CCP or non-immune fresh frozen plasma (FFP). Despite selection of CCP with significantly higher total IgG than recipients, neutralizing antibody levels did not differ between donor plasma and CCP recipients.


Biologicals ◽  
1994 ◽  
Vol 22 (3) ◽  
pp. 227-231 ◽  
Author(s):  
Bernd Lambrecht ◽  
Stephen G. Norley ◽  
Reinhard Kurth ◽  
Harald Mohr

Transfusion ◽  
1994 ◽  
Vol 34 (8) ◽  
pp. 685-689 ◽  
Author(s):  
T Zeiler ◽  
H Riess ◽  
G Wittmann ◽  
G Hintz ◽  
R Zimmermann ◽  
...  

2005 ◽  
Vol 5 (04) ◽  
pp. 178-182
Author(s):  
Wieland Kiess ◽  
Manuela Schulz ◽  
Sabine Liebermann ◽  
Roland Pfäffle ◽  
Peter Bührdel ◽  
...  

ZusammenfassungDas Smith-Lemli-Opitz-Syndrom wird durch einen Defekt des letzten Schrittes der Cholesterolbiosynthese, den Mangel an 7-Dehydrocholesterolreduktase, verursacht. Die Akkumulation der Metaboliten 7-Dehydrocholesterol und 8-Dehydrocholesterol, die die wichtigsten biochemischen Marker für die Diagnose der Erkrankung darstellen, sowie der Mangel an Cholesterol können zu multiplen kongenitalen Anomalien führen. Die Ursache des Enzymmangels sind Mutationen innerhalb des DHCR7-Gens, welches auf Chromosom 11q13 lokalisiert ist. Therapeutische Möglichkeiten bestehen in der Gabe von Cholesterol und im Notfall Fresh Frozen Plasma (FFP); der therapeutische Nutzen von Statinen befindet sich zurzeit in der klinischen Erprobung.


1976 ◽  
Vol 36 (01) ◽  
pp. 071-077 ◽  
Author(s):  
Daniel E. Whitman ◽  
Mary Ellen Switzer ◽  
Patrick A. McKee

SummaryThe availability of factor VIII concentrates is frequently a limitation in the management of classical hemophilia. Such concentrates are prepared from fresh or fresh-frozen plasma. A significant volume of plasma in the United States becomes “indated”, i. e., in contact with red blood cells for 24 hours at 4°, and is therefore not used to prepare factor VIII concentrates. To evaluate this possible resource, partially purified factor VIII was prepared from random samples of fresh-frozen, indated and outdated plasma. The yield of factor VIII protein and procoagulant activity from indated plasma was about the same as that from fresh-frozen plasma. The yield from outdated plasma was substantially less. After further purification, factor VIII from the three sources gave a single subunit band when reduced and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. These results indicate that the approximately 287,000 liters of indated plasma processed annually by the American National Red Cross (ANRC) could be used to prepare factor VIII concentrates of good quality. This resource alone could quadruple the supply of factor VIII available for therapy.


Sign in / Sign up

Export Citation Format

Share Document